. 2022 Apr 7;45(4):389–398. doi: 10.1007/s40264-022-01173-4

Table 3.

Comparison of probable or probable/definite nephrotoxic potential in the current critical care adult modified Delphi study to high-risk nephrotoxic potential in the pediatric consensus study [11]

Nephrotoxic potential	Nephrotoxins
Agreement in rating between studies (n = 16)	Amikacin, amphotericin B, cidofovir, colistin, cyclophosphamide, cyclosporine, fludarabine, gentamicin, ibuprofen, indomethacin, ketorolac, methotrexate, naproxen, tacrolimus, tobramycin, vancomycin
Discrepancy in rating between studies (n = 5)	Acyclovir (possible/probable vs high) Foscarnet (probable/definite vs moderate) Immune globulin (unlikely/possible vs high) Sirolimus (possible/probable vs high) Streptomycin (possible/probable vs high)

Nephrotoxic potential

Nephrotoxins

Agreement in rating between studies (n = 16)

Amikacin, amphotericin B, cidofovir, colistin, cyclophosphamide, cyclosporine, fludarabine, gentamicin, ibuprofen, indomethacin, ketorolac, methotrexate, naproxen, tacrolimus, tobramycin, vancomycin

Discrepancy in rating between studies (n = 5)

Acyclovir (possible/probable vs high)

Foscarnet (probable/definite vs moderate)

Immune globulin (unlikely/possible vs high)

Sirolimus (possible/probable vs high)

Streptomycin (possible/probable vs high)